{"id":"isopromethazine","rwe":[{"pmid":"6864509","year":"1983","title":"Synthesis of isopromethazine hydrochloride.","finding":"","journal":"Journal of pharmaceutical sciences","studyType":"Clinical Study"},{"pmid":"13125690","year":"1953","title":"The pharmacological differentiation of promethazine hydrochloride (phenergan) from iso-promethazine hydrochloride.","finding":"","journal":"Archives internationales de pharmacodynamie et de therapie","studyType":"Clinical Study"}],"tags":[{"label":"isopromethazine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Anti-Allergic Agents","category":"pharmacology"},{"label":"Antipruritics","category":"pharmacology"},{"label":"Dermatologic Agents","category":"pharmacology"},{"label":"Histamine Agents","category":"pharmacology"},{"label":"Histamine Antagonists","category":"pharmacology"},{"label":"Histamine H1 Antagonists","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"}],"phase":"unknown","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"prothiazin","offLabel":[],"synonyms":["isopromethazine","isomethazine","isophenergan","prothiazin"],"timeline":[],"approvals":[],"brandName":"Prothiazin","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"isopromethazine","explanation":"Imagine your brain has special locks that histamine can open to make you feel sick. Isopromethazine is like a key that blocks those locks, so histamine can't make you feel sick. This helps to reduce symptoms like nausea and vomiting.","oneSentence":"Isopromethazine works by blocking histamine receptors in the brain, which helps to reduce symptoms of nausea, vomiting, and dizziness.","technicalDetail":"Isopromethazine is a histamine H1 receptor antagonist, which means it binds to and blocks histamine receptors in the brain, reducing the effects of histamine on the central nervous system."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Isopromethazine","title":"Isopromethazine","extract":"Isopromethazine is an antihistamine and anticholinergic of the phenothiazine chemical class. It is an enantiomer of promethazine."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3761","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=isopromethazine","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=isopromethazine","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Isopromethazine","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T15:02:05.078408","biosimilars":[],"competitors":[],"genericName":"isopromethazine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04548999","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-12-03","conditions":["Multiple Sclerosis"],"enrollment":769,"completionDate":"2027-09-08"},{"nctId":"NCT07227597","phase":"PHASE1,PHASE2","title":"A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-29","conditions":["Small Cell Lung Cancer Extensive Stage"],"enrollment":170,"completionDate":"2030-12-30"},{"nctId":"NCT07401836","phase":"NA","title":"Standardized Sleep Bundle for Cardiac Surgery Patients","status":"RECRUITING","sponsor":"Horizon Health Network","startDate":"2026-03-02","conditions":["Sleep"],"enrollment":20,"completionDate":"2026-06"},{"nctId":"NCT06170788","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-15","conditions":["Non-small Cell Lung Cancer (NSCLC)"],"enrollment":614,"completionDate":"2030-05-27"},{"nctId":"NCT05501678","phase":"PHASE2","title":"Trial of Diphenhydramine for Sleep in Children With Autism","status":"RECRUITING","sponsor":"Stanford University","startDate":"2023-08-09","conditions":["Autism","Autism Spectrum Disorder"],"enrollment":26,"completionDate":"2027-12-31"},{"nctId":"NCT07223671","phase":"PHASE1","title":"Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2025-12-31","conditions":["Healthy Volunteers"],"enrollment":30,"completionDate":"2026-03-19"},{"nctId":"NCT05540574","phase":"PHASE2","title":"Trial of Zolpidem for Sleep in Children With Autism","status":"RECRUITING","sponsor":"Stanford University","startDate":"2023-08-09","conditions":["Autism","Autism Spectrum Disorder"],"enrollment":26,"completionDate":"2028-04-30"},{"nctId":"NCT07300670","phase":"PHASE1","title":"The Effect of Losartan on Cephalexin","status":"RECRUITING","sponsor":"Aleksi Tornio","startDate":"2026-03-04","conditions":["Possible Interaction Between Losartan and Cephalexin","Healthy"],"enrollment":12,"completionDate":"2026-05-08"},{"nctId":"NCT07163429","phase":"NA","title":"Efficacy of Flurbiprofen Spray for Postoperative Sore Throat Following Double-Lumen Endobronchial Intubation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kittitorn Supphapipat, MD","startDate":"2025-09-10","conditions":["Post Operative Sore Throat","Hoarseness"],"enrollment":58,"completionDate":"2027-06-30"},{"nctId":"NCT00342888","phase":"","title":"Case-Control Study of Pesticides and Childhood Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-10-30","conditions":["Leukemia"],"enrollment":629,"completionDate":""},{"nctId":"NCT04268498","phase":"PHASE2","title":"A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2020-02-11","conditions":["Multiple Myeloma"],"enrollment":310,"completionDate":"2027-02-01"},{"nctId":"NCT04375384","phase":"PHASE2","title":"Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2020-07-01","conditions":["Head and Neck Squamous Cell Carcinoma","Recurrent Head and Neck Squamous Cell Carcinoma","Metastatic Head-and-neck Squamous-cell Carcinoma"],"enrollment":38,"completionDate":"2027-12"},{"nctId":"NCT05012631","phase":"PHASE2","title":"Losartan for Diffuse Myocardial Fibrosis in Sickle Cell Disease","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2021-09-01","conditions":["Sickle Cell Disease","Diffuse Myocardial Fibrosis"],"enrollment":24,"completionDate":"2027-12-31"},{"nctId":"NCT07478315","phase":"NA","title":"IMPOWER-QoL: IMPact Of Discontinuing Premedication for WEekly Paclitaxel on bReast Cancer Patient's Quality Of Life","status":"NOT_YET_RECRUITING","sponsor":"Charles LeMoyne Hospital","startDate":"2026-03-15","conditions":["Breast Cancer"],"enrollment":50,"completionDate":"2026-12-31"},{"nctId":"NCT07136415","phase":"PHASE4","title":"Comparing Digital Therapy, Trazodone, and Daridorexant for Menopause-Related Insomnia Symptoms","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-02-13","conditions":["Menopausal Women","Insomnia"],"enrollment":1000,"completionDate":"2031-02"},{"nctId":"NCT03258593","phase":"PHASE1","title":"Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-06-07","conditions":["Urinary Bladder Neoplasms"],"enrollment":15,"completionDate":"2022-10-17"},{"nctId":"NCT07472413","phase":"PHASE3","title":"Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project","status":"NOT_YET_RECRUITING","sponsor":"University of Miami","startDate":"2026-07-01","conditions":["Multiple Sclerosis"],"enrollment":60,"completionDate":"2028-07-01"},{"nctId":"NCT07472270","phase":"PHASE1","title":"Safety Evaluation of MSC-based Therapy for Liver Cihcrosis Treatment","status":"NOT_YET_RECRUITING","sponsor":"Vinmec Research Institute of Stem Cell and Gene Technology","startDate":"2026-03-15","conditions":["Liver Cirrhosis"],"enrollment":12,"completionDate":"2026-12-31"},{"nctId":"NCT05627232","phase":"PHASE1","title":"Tazemetostat and Palbociclib With CPX-351for R/R AML","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2023-08-28","conditions":["Recurrent Acute Myeloid Leukemia","Refractory Acute Myeloid Leukemia"],"enrollment":24,"completionDate":"2029-01"},{"nctId":"NCT06043323","phase":"PHASE2","title":"A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-01-08","conditions":["Follicular Lymphoma"],"enrollment":20,"completionDate":"2028-09-01"},{"nctId":"NCT06211335","phase":"PHASE1","title":"Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2023-12-07","conditions":["Locally Recurrent Head and Neck Squamous Cell Carcinoma","Metastatic Head and Neck Squamous Cell Carcinoma","Refractory Head and Neck Squamous Cell Carcinoma"],"enrollment":24,"completionDate":"2027-06"},{"nctId":"NCT05896228","phase":"PHASE2","title":"Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Benjamin T Diamond, MD","startDate":"2024-02-20","conditions":["Refractory Multiple Myeloma","Relapsed Multiple Myeloma"],"enrollment":30,"completionDate":"2031-03-01"},{"nctId":"NCT05807048","phase":"PHASE2","title":"Daratumumab in STK11 Mutated NSCLC","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2023-06-01","conditions":["Non-small Cell Lung Cancer With STK11/LKB1 Mutation"],"enrollment":8,"completionDate":"2025-11-11"},{"nctId":"NCT04862221","phase":"PHASE2","title":"TReatment for ImmUne Mediated PathopHysiology","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2022-02-09","conditions":["Acute Liver Failure","Fulminant Hepatic Failure","Hepatic Encephalopathy","Acute Liver Injury","Immune Dysregulation"],"enrollment":163,"completionDate":"2027-02"},{"nctId":"NCT07461727","phase":"PHASE1","title":"An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-02-10","conditions":["Non-Small Cell Lung Cancer","Metastatic Non-small Cell Lung Cancer","Liver Metastases","EGFR Gene Mutation","EGFR L858R"],"enrollment":15,"completionDate":"2029-01-31"},{"nctId":"NCT02858310","phase":"PHASE1,PHASE2","title":"E7 TCR T Cells for Human Papillomavirus-Associated Cancers","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-01-27","conditions":["Papillomavirus Infections","Cervical Intraepithelial Neoplasia","Carcinoma In Situ","Vulvar Neoplasms","Vulvar Diseases"],"enrollment":224,"completionDate":"2025-07-02"},{"nctId":"NCT05039619","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-05-12","conditions":["Lupus Nephritis"],"enrollment":40,"completionDate":"2030-06-14"},{"nctId":"NCT06566794","phase":"NA","title":"KF2022#4-trial: Effects of a Beta Blocker and NSAID on CYP Mediated Drug Metabolism","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2024-08-22","conditions":["Drug Interaction"],"enrollment":12,"completionDate":"2025-01-10"},{"nctId":"NCT07449000","phase":"NA","title":"Losartan for Corneal Fibrosis","status":"RECRUITING","sponsor":"Universidad Autonoma de Nuevo Leon","startDate":"2026-02-12","conditions":["Corneal Scarring Fibrosis"],"enrollment":46,"completionDate":"2027-03-01"},{"nctId":"NCT07435311","phase":"PHASE1","title":"A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2020-06-15","conditions":["Head and Neck Squamous Cell Carcinoma"],"enrollment":118,"completionDate":"2024-07-17"},{"nctId":"NCT05662228","phase":"PHASE2","title":"Therapies for Down Syndrome Regression Disorder","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2023-06-29","conditions":["Down Syndrome","Regression"],"enrollment":66,"completionDate":"2026-12"},{"nctId":"NCT07435324","phase":"PHASE3","title":"A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"R-Pharm","startDate":"2024-08-08","conditions":["Head and Neck Squamous Cell Carcinoma"],"enrollment":161,"completionDate":"2026-06-21"},{"nctId":"NCT06078696","phase":"PHASE1,PHASE2","title":"Siplizumab for Sickle Cell Disease Transplant","status":"TERMINATED","sponsor":"Columbia University","startDate":"2023-09-28","conditions":["Anemia, Sickle Cell"],"enrollment":1,"completionDate":"2025-12-11"},{"nctId":"NCT06748404","phase":"PHASE2","title":"TriCalm Hydrogel® in the Treatment of Immunotherapy-Related Pruritus","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2025-01-31","conditions":["Immunotherapy-related Pruritus"],"enrollment":28,"completionDate":"2028-12"},{"nctId":"NCT06356571","phase":"PHASE2","title":"A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-03-17","conditions":["Plasma Cell Myeloma Refractory"],"enrollment":64,"completionDate":"2027-07-15"},{"nctId":"NCT04224558","phase":"PHASE1,PHASE2","title":"Stem Cell Transplantation in Crohn's Disease","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2019-11-15","conditions":["Crohn Disease"],"enrollment":15,"completionDate":"2027-09-30"},{"nctId":"NCT03417388","phase":"PHASE4","title":"Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2018-02-09","conditions":["Coronary Artery Disease"],"enrollment":2476,"completionDate":"2026-09-14"},{"nctId":"NCT07268248","phase":"NA","title":"1-hour Premedication for Allergy Goal in Emergency: PAGE-1 Study","status":"NOT_YET_RECRUITING","sponsor":"Paul Peng, MD PhD MSCR","startDate":"2026-06","conditions":["Allergic Reaction to Contrast Media","Hypersensitivity Reaction","Computed Tomography","Premedication"],"enrollment":540,"completionDate":"2028-06"},{"nctId":"NCT04432597","phase":"PHASE1,PHASE2","title":"HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-08-11","conditions":["HPV Positive Cancer","Vulvar, Vaginal, Penile, Rectal Cancer","Anal Cancer","Oropharyngeal Cancer","Cervical Cancer"],"enrollment":39,"completionDate":"2026-03-31"},{"nctId":"NCT07235748","phase":"PHASE1","title":"Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier (I.R.I.S.)","startDate":"2025-10-07","conditions":["Healthy Adult Participants"],"enrollment":28,"completionDate":"2025-12-23"},{"nctId":"NCT04544436","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-11-26","conditions":["Multiple Sclerosis"],"enrollment":864,"completionDate":"2028-08-31"},{"nctId":"NCT06074588","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-11-12","conditions":["Non-small Cell Lung Cancer (NSCLC)"],"enrollment":556,"completionDate":"2030-03-11"},{"nctId":"NCT06041529","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yuhan Corporation","startDate":"2023-10-18","conditions":["Essential Hypertension"],"enrollment":198,"completionDate":"2026-02-28"},{"nctId":"NCT03913559","phase":"PHASE2","title":"Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-05-14","conditions":["Acute Lymphoblastic Leukemia"],"enrollment":5,"completionDate":"2025-09-15"},{"nctId":"NCT04580134","phase":"PHASE4","title":"CLOZAPINE Response in Biotype-1","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2022-03-01","conditions":["Schizophrenia","Schizoaffective Disorder","Bipolar 1 Disorder"],"enrollment":524,"completionDate":"2026-04-01"},{"nctId":"NCT04221477","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-08-10","conditions":["Lupus Nephritis"],"enrollment":271,"completionDate":"2031-02-28"},{"nctId":"NCT04918147","phase":"PHASE2","title":"Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-10-13","conditions":["IgG4 Related Disease","IgG4-RD"],"enrollment":8,"completionDate":"2024-01-04"},{"nctId":"NCT04743661","phase":"PHASE2","title":"131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pediatric Brain Tumor Consortium","startDate":"2022-04-04","conditions":["Recurrent Medulloblastoma","Recurrent Ependymoma"],"enrollment":62,"completionDate":"2027-09-30"},{"nctId":"NCT03900793","phase":"PHASE1","title":"Losartan + Sunitinib in Treatment of Osteosarcoma","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2019-08-26","conditions":["Osteosarcoma"],"enrollment":41,"completionDate":"2027-02"},{"nctId":"NCT01391962","phase":"PHASE2","title":"Sunitinib or Cediranib for Alveolar Soft Part Sarcoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-07-18","conditions":["Sarcoma, Alveolar Soft Part"],"enrollment":34,"completionDate":"2026-01-16"},{"nctId":"NCT07370506","phase":"PHASE1,PHASE2","title":"Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2026-02","conditions":["Breast Cancer","Doxorubicin Induced Cardiomyopathy"],"enrollment":36,"completionDate":"2027-02"},{"nctId":"NCT04681105","phase":"PHASE1","title":"Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2020-11-18","conditions":["Recurrent Acute Leukemia","Recurrent B Acute Lymphoblastic Leukemia","Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm","Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Recurrent Hairy Cell Leukemia","Recurrent Hematologic Malignancy","Recurrent Hodgkin Lymphoma","Recurrent T Acute Lymphoblastic Leukemia","Refractory Acute Leukemia","Refractory B Acute Lymphoblastic Leukemia","Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm","Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Refractory Hairy Cell Leukemia","Refractory Hematologic Malignancy","Refractory Hodgkin Lymphoma","Refractory T Acute Lymphoblastic Leukemia","Systemic Mastocytosis"],"enrollment":13,"completionDate":"2025-08-05"},{"nctId":"NCT06815497","phase":"PHASE2","title":"Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer","status":"RECRUITING","sponsor":"Tyler J Curiel","startDate":"2026-01-21","conditions":["Ovarian Cancer"],"enrollment":33,"completionDate":"2029-05-14"},{"nctId":"NCT07364344","phase":"NA","title":"Safety and Preliminary Efficacy of Hibernation-Like Therapy (Chlorpromazine and Promethazine) in Patients With Acute Ischemic Stroke (AIS) Eligible for Reperfusion Therapy.","status":"NOT_YET_RECRUITING","sponsor":"Ji Xunming,MD,PhD","startDate":"2026-01","conditions":["Acute Ischemic Stroke"],"enrollment":57,"completionDate":"2026-07"},{"nctId":"NCT07360002","phase":"NA","title":"The Randomized Controlled Study of Shenqi Yishen Granules in the Treatment of IgA Nephropathy","status":"NOT_YET_RECRUITING","sponsor":"Keda Lu","startDate":"2026-01","conditions":["IgA Nephropathy (IgAN)"],"enrollment":102,"completionDate":"2026-12"},{"nctId":"NCT07358689","phase":"PHASE2","title":"Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-01-30","conditions":["NSCLC"],"enrollment":120,"completionDate":"2029-01-01"},{"nctId":"NCT06428409","phase":"PHASE1,PHASE2","title":"A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-20","conditions":["Colorectal Cancer","Pancreatic Ductal Adenocarcinoma","Biliary Tract Cancer"],"enrollment":220,"completionDate":"2029-10-16"},{"nctId":"NCT05219604","phase":"PHASE4","title":"Central Nervous System Effects Following Infusion of Diphenhydramine Using Pharmacokinetic and Pharmacodynamic Modeling","status":"TERMINATED","sponsor":"Dent Neuroscience Research Center","startDate":"2022-03-15","conditions":["Central Nervous System Effects of Diphenhydramine","Pharmacokinetics of Diphenhydramine"],"enrollment":3,"completionDate":"2022-10-04"},{"nctId":"NCT06962631","phase":"PHASE3","title":"V-IMMUNE® for Immune Thrombocytopenia","status":"RECRUITING","sponsor":"On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA.","startDate":"2025-07-18","conditions":["Immune Thrombocytopenia (ITP)"],"enrollment":31,"completionDate":"2027-02-27"},{"nctId":"NCT06933706","phase":"PHASE2","title":"Losartan to Improve Outcomes After Multi-ligament Knee Injury","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2025-10-01","conditions":["Multi-ligament Knee Injury"],"enrollment":90,"completionDate":"2029-09-30"},{"nctId":"NCT06954441","phase":"PHASE3","title":"V-IMMUNE: A Novel Immunoglobulin Therapy for Immunodeficiency","status":"RECRUITING","sponsor":"On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA.","startDate":"2025-08-15","conditions":["Immunodeficiencies","Primary Immunodeficiencies (PID)","Agammaglobulinemia"],"enrollment":50,"completionDate":"2027-02-27"},{"nctId":"NCT06083571","phase":"PHASE2","title":"Intranasal Ketorolac Trial","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2024-01-01","conditions":["Headache, Migraine"],"enrollment":41,"completionDate":"2025-12-31"},{"nctId":"NCT04539808","phase":"PHASE2","title":"NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2021-05-27","conditions":["Pancreatic Adenocarcinoma","Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8","Stage I Pancreatic Cancer American Joint Committee on Cancer v8","Stage III Pancreatic Cancer American Joint Committee on Cancer v8","Stage IV Pancreatic Cancer American Joint Committee on Cancer v8"],"enrollment":42,"completionDate":"2027-01-05"},{"nctId":"NCT02604199","phase":"PHASE2","title":"A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-09","conditions":["Hepatitis B"],"enrollment":58,"completionDate":"2017-01"},{"nctId":"NCT02577029","phase":"PHASE2","title":"Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-12","conditions":["Hepatitis B","Hepatitis D"],"enrollment":79,"completionDate":"2016-12"},{"nctId":"NCT06207305","phase":"PHASE1,PHASE2","title":"A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-01-30","conditions":["Metastatic Appendiceal Adenocarcinoma","Intraperitoneal Paclitaxel"],"enrollment":39,"completionDate":"2028-01-02"},{"nctId":"NCT02738008","phase":"PHASE2","title":"Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2016-03","conditions":["Hepatitis B"],"enrollment":12,"completionDate":"2016-12"},{"nctId":"NCT02604212","phase":"PHASE2","title":"A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-11","conditions":["Hepatitis B"],"enrollment":32,"completionDate":"2016-12"},{"nctId":"NCT02535416","phase":"PHASE1","title":"A Study of ARC-520 at Varying Infusion Rates in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-09","conditions":["Healthy"],"enrollment":40,"completionDate":"2016-08"},{"nctId":"NCT02363946","phase":"PHASE1","title":"A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD)","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-02","conditions":["Alpha-1 Antitrypsin Deficiency"],"enrollment":65,"completionDate":"2016-11"},{"nctId":"NCT02797522","phase":"PHASE1","title":"A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2016-06","conditions":["Hepatitis B"],"enrollment":47,"completionDate":"2016-11"},{"nctId":"NCT06132958","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-06","conditions":["Endometrial Cancer"],"enrollment":710,"completionDate":"2028-01-10"},{"nctId":"NCT06124118","phase":"PHASE1","title":"Tumor Treating Fields for Locally Advanced NSCLC","status":"RECRUITING","sponsor":"University of Utah","startDate":"2024-04-04","conditions":["Non Small Cell Lung Cancer"],"enrollment":30,"completionDate":"2027-11-15"},{"nctId":"NCT07324889","phase":"PHASE1,PHASE2","title":"An Open-label, Single-arm, Prospective, Multicenter, Phase I/II Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-T Cell Therapy for Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia","status":"NOT_YET_RECRUITING","sponsor":"Yihao Wang","startDate":"2026-01-31","conditions":["Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia"],"enrollment":24,"completionDate":"2027-10-31"},{"nctId":"NCT05211336","phase":"PHASE1","title":"Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-04-19","conditions":["Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS)","Aggressive B-cell Lymphoma With Secondary Involvement of the CNS"],"enrollment":14,"completionDate":"2029-06-01"},{"nctId":"NCT05056727","phase":"PHASE3","title":"A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2021-09-30","conditions":["Renal Insufficiency, Chronic","Hyperkalemia"],"enrollment":1112,"completionDate":"2024-02-07"},{"nctId":"NCT00659035","phase":"","title":"Use of Driving Tests to Evaluate Patient Performance on Oral Opioids","status":"ACTIVE_NOT_RECRUITING","sponsor":"Asokumar Buvanendran","startDate":"2008-04","conditions":["Chronic Pain"],"enrollment":450,"completionDate":"2026-12"},{"nctId":"NCT04629248","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-06-25","conditions":["Primary Membranous Nephropathy"],"enrollment":142,"completionDate":"2027-12-21"},{"nctId":"NCT04963296","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-26","conditions":["Systemic Lupus Erythematosus"],"enrollment":303,"completionDate":"2028-03-14"},{"nctId":"NCT06910241","phase":"PHASE3","title":"Lidocaine Versus Diphenhydramine to Achieve Local Anesthesia for Laceration Repairs","status":"RECRUITING","sponsor":"Florida Atlantic University","startDate":"2025-09-03","conditions":["Laceration of Skin"],"enrollment":100,"completionDate":"2028-06-30"},{"nctId":"NCT06692452","phase":"PHASE2","title":"Tazemetostat Plus CHOP in 1L T-cell Lymphoma","status":"SUSPENDED","sponsor":"Eric Jacobsen, MD","startDate":"2024-12-24","conditions":["Lymphoma","Peripheral T Cell Lymphoma","Angioimmunoblastic T-cell Lymphoma","Enteropathy-Associated T-Cell Lymphoma","Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma"],"enrollment":24,"completionDate":"2032-10-01"},{"nctId":"NCT05704049","phase":"PHASE2","title":"A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2023-04-05","conditions":["Relapsed/Refractory Multiple Myeloma"],"enrollment":118,"completionDate":"2028-05-12"},{"nctId":"NCT07285031","phase":"NA","title":"Histamines and Central Hemodynamics","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2025-12","conditions":["Histamine","Exercise"],"enrollment":20,"completionDate":"2026-08"},{"nctId":"NCT06070649","phase":"PHASE1","title":"The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD)","status":"RECRUITING","sponsor":"Yale University","startDate":"2025-08-04","conditions":["Alcohol Use Disorder (AUD)","Alcohol-Related Disorders","Alcohol Use"],"enrollment":63,"completionDate":"2026-08-01"},{"nctId":"NCT01451502","phase":"NA","title":"Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2011-10-20","conditions":["Lymphatic Diseases","Hematopoietic Malignancy"],"enrollment":250,"completionDate":"2026-12"},{"nctId":"NCT07062627","phase":"PHASE2","title":"Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma","status":"RECRUITING","sponsor":"Hyungwoo Cho","startDate":"2025-11-12","conditions":["Primary CNS Lymphoma (PCNSL)","Diffuse Large B Cell Lymphoma (DLBCL)"],"enrollment":12,"completionDate":"2027-12-31"},{"nctId":"NCT07283575","phase":"","title":"Using ctDNA Methylation to Monitor Metastatic Colorectal Cancer Treatment (PROMET)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-10-10","conditions":["Metastatic Colorectal Cancer ctDNA Surveillance"],"enrollment":497,"completionDate":"2030-10-10"},{"nctId":"NCT07135687","phase":"PHASE4","title":"Study to Use Oral Losartan to Decrease the Risk of Postoperative Scarring Following (ACL) Reconstruction","status":"NOT_YET_RECRUITING","sponsor":"Rush University Medical Center","startDate":"2026-08","conditions":["ACL Injury","ACL Reconstruction","Scar Formation"],"enrollment":144,"completionDate":"2028-12"},{"nctId":"NCT05627557","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-03-29","conditions":["Childhood Idiopathic Nephrotic Syndrome"],"enrollment":85,"completionDate":"2026-09-04"},{"nctId":"NCT04270409","phase":"PHASE3","title":"Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2020-06-16","conditions":["Plasma Cell Myeloma"],"enrollment":337,"completionDate":"2033-10-21"},{"nctId":"NCT07265739","phase":"PHASE2","title":"Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-04","conditions":["Platinum Resistant Ovarian Cancer"],"enrollment":27,"completionDate":"2028-12-30"},{"nctId":"NCT06483789","phase":"PHASE2","title":"Efficacy and Safety of HB-1 for Panic Disorder","status":"RECRUITING","sponsor":"Honeybrains Biotech LLC","startDate":"2024-10-29","conditions":["Panic Disorder","Mental Illness"],"enrollment":240,"completionDate":"2027-02"},{"nctId":"NCT05619653","phase":"PHASE3","title":"Myocardial Protection in Patients With Post-acute Inflammatory Cardiac Involvement Due to COVID-19","status":"ACTIVE_NOT_RECRUITING","sponsor":"Valentina Puentmann","startDate":"2022-12-12","conditions":["COVID-19 Associated Cardiac Involvement","Remodeling, Left Ventricle","Remodeling, Vascular","Left Ventricular Dysfunction","Exercise Intolerance","Vascular Inflammation","Microvascular Angina","Long COVID","Myocarditis, Pericarditis"],"enrollment":279,"completionDate":"2026-03-31"},{"nctId":"NCT03997851","phase":"PHASE1,PHASE2","title":"Topical Acetaminophen for Itch Relief: a Proof of Concept Study in Healthy Subjects","status":"COMPLETED","sponsor":"University of Miami","startDate":"2019-07-22","conditions":["Pruritus"],"enrollment":17,"completionDate":"2020-03-18"},{"nctId":"NCT02473042","phase":"NA","title":"Intraoperative Acupoint Stimulation to Prevent Post-Operative Nausea and Vomiting (PONV)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-03-01","conditions":["Post-Operative Nausea and Vomiting","Breast Cancer"],"enrollment":188,"completionDate":"2024-11-26"},{"nctId":"NCT06645678","phase":"PHASE1,PHASE2","title":"Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"YOUNGIL KOH","startDate":"2024-11-26","conditions":["Relapsed Refractory Multiple Myeloma (RRMM)"],"enrollment":75,"completionDate":"2027-10-01"},{"nctId":"NCT07259070","phase":"PHASE1,PHASE2","title":"Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-11-29","conditions":["DLBCL","CLL","FL","MCL","WM","MZL"],"enrollment":20,"completionDate":"2029-11-28"},{"nctId":"NCT06120673","phase":"PHASE3","title":"REmission in Membranous Nephropathy International Trial (REMIT)","status":"WITHDRAWN","sponsor":"The University of Queensland","startDate":"2025-10-31","conditions":["Primary Membranous Nephropathy"],"enrollment":0,"completionDate":"2028-01-31"},{"nctId":"NCT05977998","phase":"PHASE2","title":"A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-09-08","conditions":["Gastric Adenocarcinoma","Carcinomatosis"],"enrollment":30,"completionDate":"2030-10-31"},{"nctId":"NCT05077800","phase":"PHASE2","title":"FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Colin D. Weekes, M.D., PhD","startDate":"2022-03-21","conditions":["Pancreatic Adenocarcinoma","Pancreatic Adenocarcinoma Metastatic"],"enrollment":70,"completionDate":"2026-07-31"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"044033O3TY","CHEBI":"CHEBI:135176","UMLSCUI":"C0022232","PUBCHEM_CID":"110669","MESH_DESCRIPTOR_UI":"D011398"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":2,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"1983 May","pmid":"6864509","title":"Synthesis of isopromethazine hydrochloride.","journal":"Journal of pharmaceutical sciences"},{"date":"1953 Sep 15","pmid":"13125690","title":"The pharmacological differentiation of promethazine hydrochloride (phenergan) from iso-promethazine hydrochloride.","journal":"Archives internationales de pharmacodynamie et de therapie"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Prothiazin, also known as isopromethazine, is a small molecule drug in the isopromethazine class. Its exact target is unknown, but it is used to treat various conditions. Unfortunately, there is limited information available on its commercial status, approved indications, and pharmacokinetic properties. Further research is needed to fully understand its mechanism of action and safety profile. As a result, it is not possible to provide a comprehensive summary of this medication.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}